While the anti-tumor activity of VISTA biologics has been previously described2–7,14,26–29, we specifically assessed the anti-tumor activity of SNS-101, both as standalone treatment and in combination with anti-mouse PD-1 (anti-mPD-1) across various syngeneic mouse models (Fig. 6 and Supplementary Fig. 11). This evidence concerns the gene PDCD1 and neoplasm.